Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

IQVIA’s FluSTAR Online Dynamic Platform Helps Consumers Track Local Rates of Flu, Allergy and Asthma

IQVIA – a leader in human data science – provides consumers with quick and easy access to seasonal suffering data, giving them unique insights into important health related information. Recent data show that flu season is hitting hard in several key markets.

Read More »

Sanofi’s pediatric hexavalent vaccine approved by U.S. FDA

The U.S. Food and Drug Administration approved Sanofi’s new pediatric vaccine immunizing children against six diseases.

Read More »

Roche flu drug speeds relief from symptoms in at-risk patients

Roche said a late-stage clinical trial has shown the Swiss drugmaker’s influenza drug baloxavir marboxil significantly sped time to relief for patients highly vulnerable to serious complications.

Read More »

Pfizer bets on biotech flu vaccine in BioNTech alliance

Pfizer will pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest major pharma company to bank on a promising new genetic approach.

Read More »

Roche Q2 2018 Financials: “Firing on All Cylinders”

Switzerland-based Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of 2018 and a 20 percent increase in its core EPS.

Read More »

Roche touts new flu drug

Roche’s hopes of recapturing lost ground in the generics-flooded influenza market got a boost after a late-stage study showed the Swiss drugmaker’s new medicine reduced symptoms in people at high risk of complications.

Read More »

FDA Grants Priority Review to Genentech’s Baloxavir Marboxil for the Treatment of Influenza

The U.S. FDA accepted a New Drug Application and granted Priority Review for Genentech’s baloxavir marboxil as a single-dose, oral treatment for acute, uncomplicated influenza in people 12 years and older.

Read More »

Statement from FDA Commissioner Scott Gottlieb, M.D. on the efficacy of the 2017-2018 influenza vaccine

Seasonal flu has been widespread in 2018, impacting millions of people across the country. It has been an especially challenging season, with high rates of hospitalization for both influenza and its complications, which include pneumonia and the exacerbation of chronic conditions such as asthma and congestive heart failure. Many schools have closed in an attempt to control the spread of the illness and doctor’s offices are packed with patients seeking diagnosis and antiviral treatment.

Read More »

Germany’s CureVac wins new vaccine funding from Gates Foundation

German biotech firm CureVac secured more financial backing for vaccine development projects from its investor the Bill & Melinda Gates Foundation, working on jabs to prevent malaria and influenza.

Read More »

Google venture arm backs UK universal flu vaccine company

A private British company is developing a vaccine that would be the first in the world to fight all types of flu.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom